Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse

Cancer Biology and Therapy

Volumn 17, Issue 11, 2016, Pages 1213-1220

  Nardone, Valerio ^a,b   Botta, Cirino ^c   Caraglia, Michele ^d   Martino, Elodia Claudia ^a   Ambrosio, Maria Raffaella ^e   Carfagno, Tommaso ^a,b   Tini, Paolo ^a,b   Semeraro, Leonardo ^a,b   Misso, Gabriella ^d   Grimaldi, Anna ^d   Boccellino, Mariarosaria ^d   Facchini, Gaetano ^f   Berretta, Massimiliano ^g   Vischi, Gianluca ^a,b   Rocca, Bruno Jim ^e,h   Barone, Aurora ^e   Tassone, Pierfrancesco ^c   Tagliaferri, Pierosandro ^c   del Vecchio, Maria Teresa ^e   Pirtoli, Luigi ^a,b   Correale, Pierpaolo ^a,b   more..

^a UNIVERSITY OF SIENA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Chemokyne Receptor 7; disease free survival; FoxP3; overall survival; PD 1; prognosis; prostate cancer; radiotherapy; T regulators lymphocytes; tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; PROGRAMMED DEATH 1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR FOXP3; CCR7 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ADVANCED CANCER; AGED; ARTICLE; BIOCHEMICAL PROGRESSION FREE SURVIVAL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; BIOSYNTHESIS; IMMUNOLOGY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RECURRENT DISEASE; SALVAGE THERAPY; TUMOR MICROENVIRONMENT;

AGED; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSTATIC NEOPLASMS; RECEPTORS, CCR7; RECURRENCE; SALVAGE THERAPY; TUMOR MICROENVIRONMENT;

EID: 84997284759     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1235666     Document Type: Article

References (66)

1. Ambrosio MR, Pirtoli L, Del Vecchio MT. Emerging targets for prostate adenocarcinoma therapy:How molecular biology may drive towards a more tailored approach. Current Drug Targets 2015; 17:266–75; PMID:26477458; http://dx.doi.org/10.2174/1389450116666151019102220
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer J Int Du Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
3. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival:long-term followup of a randomized clinical trial. J Urol 2009; 181:956-62; PMID:19167731; http://dx.doi.org/10.1016/j.juro.2008.11.032
4. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer:long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380:2018-27; PMID:23084481; http://dx.doi.org/10.1016/S0140-6736(12)61253-7
5. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy:10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 2014; 66:243-50; PMID:24680359; http://dx.doi.org/10.1016/j.eururo.2014.03.011
6. Ying J, Wang CJ, Yan J, Liauw SL, Straka C, Pistenmaa D, Xie XJ, Lotan Y, Roehrborn C, Kim DN. Long-term outcome of prostate cancer patients who exhibit biochemical failure despite salvage radiation therapy after radical prostatectomy. Am J Clin Oncol 2015; PMID:26165416; http://dx.doi.org/10.1097/COC.0000000000000207
7. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004; 171:679-83; PMID:14713785; http://dx.doi.org/10.1097/01.ju.0000106190.32540.6c
8. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180:921-27; PMID:18635218; http://dx.doi.org/10.1016/j.juro.2008.05.045
9. Vitale G, Lupoli G, Guarrasi R, Colao A, Dicitore A, Gaudenzi G, Misso G, Castellano M, Addeo R, Facchini G, et al. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer:in vitro and in vivo studies. J Clin Endocrinol Metab 2013; 98:E1567-74; PMID:23884781; http://dx.doi.org/10.1210/jc.2013-1443
10. Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D, Persani L, Arra C, Vitale G. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ):at the cross-road of pancreatic cancer cell proliferation. Biochim Et Biophys Acta 2014; 1845:42-52; PMID:24295567; http://dx.doi.org/10.1016/j.bbcan.2013.11.003
11. Vitale G, van Koetsveld PM, de Herder WW, van der Wansem K, Janssen JA, Colao A, Lombardi G, Lamberts SWJ, Hofland LJ. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. American journal of physiology. Endocrinol Metab 2009; 296:E559-66; PMID:19141687; http://dx.doi.org/10.1152/ajpendo.90770.2008
12. Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer:Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015; 68:267-79; PMID:25824720; http://dx.doi.org/10.1016/j.eururo.2015.02.032
13. Simons JW. Prostate cancer immunotherapy:beyond immunity to curability. Cancer Immunol Res 2014; 2:1034-43; PMID:25367978; http://dx.doi.org/10.1158/2326-6066.CIR-14-0174
14. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998; 161:3186-94; PMID:9743387
15. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997; 89:293-300; PMID:9048833; http://dx.doi.org/10.1093/jnci/89.4.293/content/89/4/293.abstract
16. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation andtreatment effectiveness. Lancet Oncol 2014; 15:e493-503; PMID:25281468; http://dx.doi.org/10.1016/S1470-2045(14)70263-3
17. Talebian Yazdi M, van Riet S, van Schadewijk A, Fiocco M, van Hall T, Taube C, Hiemstra PS, Van Der Burg SH. The positive prognostic effect of stromal CD8C tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget 2015; 7:3477–88; PMID:26658106; http://dx.doi.org/10.18632/oncotarget.6506
18. McCoy MJ, Hemmings C, Miller TJ, Austin SJ, Bulsara MK, Zeps N, Nowak AK, Lake RA, Platell CF. Low stromal Foxp3(+) regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. Br J Cancer 2015; 113:1677-86; PMID:26645238; http://dx.doi.org/10.1038/bjc.2015.427
19. Daster S, Eppenberger-Castori S, Hirt C, Soysal SD, Delko T, Nebiker CA, Weixler B, Amicarella F, Iezzi G, Governa V, et al. Absence of myeloperoxidase and CD8 positive cells in colorectal cancer infiltrates identifies patients with severe prognosis. Oncoimmunology 2015; 4:e1050574; PMID:26587320; http://dx.doi.org/10.1080/2162402X.2015.1050574
20. van Harten-Gerritsen AS, Balvers MG, Witkamp RF, Kampman E, van Duijnhoven FJ. Vitamin D, inflammation, and colorectal cancer progression:A review of mechanistic studies and future directions for epidemiological studies. Cancer Epidemiol Biomarkers Prevention 2015; 24:1820-8; PMID:26396142; http://dx.doi.org/10.1158/1055-9965.EPI-15-0601
21. Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Therapy 2013; 14:469-75; PMID:23760488; http://dx.doi.org/10.4161/cbt.24425
22. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res 2008; 14:4192-9; PMID:18593999; http://dx.doi.org/10.1158/1078-0432.CCR-07-5278
23. Correale P, Botta C, Martino E, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, et al. Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. Oncoimmunology 2015; 5(4):e1101205; PMID:27141384; http://dx.doi.org/10.1080/2162402X.2015.1101205
24. Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, et al. Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients:the GOLFIG-2 multicentric open-label randomized phase III trial. J Immunotherapy 2014; 37:26-35; PMID:24316553; http://dx.doi.org/10.1097/CJI.0000000000000004
25. Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, et al. Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. Cancer Immunol Immunother 2015; 64:1159-73; PMID:26031574; http://dx.doi.org/10.1007/s00262-015-1711-7
26. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010; 33:435-41; PMID:20386463; http://dx.doi.org/10.1097/CJI.0b013e3181d32f01
27. Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P, et al. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res 2012; 18:850-7; PMID:22142823; http://dx.doi.org/10.1158/1078-0432.CCR-10-3186
28. Correale P, Rotundo MS, Botta C, Del Vecchio MT, Tassone P, Tagliaferri P. Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. Oncoimmunology 2012; 1:531-2; PMID:22754775; http://dx.doi.org/10.4161/onci.19404
29. Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh AC, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC radiation oncology group. Radiother Oncol 2007; 84:121-7; PMID:17706307; http://dx.doi.org/10.1016/j.radonc.2007.07.017
30. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping:data based on the modified Gleason scoring system. BJU Int 2013; 111:753-60; PMID:23464824; http://dx.doi.org/10.1111/j.1464-410X.2012.11611.x
31. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015; 28:690-714; PMID:26678337; http://dx.doi.org/10.1016/j.ccell.2015.10.012
32. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013; 73:2782-94; PMID:23418320; http://dx.doi.org/10.1158/0008-5472.CAN-12-3981
33. Frey B, Gaipl US. Radio-immunotherapy:the focused beam expands. Lancet Oncol 2015; 16:742-3; PMID:26095779; http://dx.doi.org/10.1016/S1470-2045(15)00055-8
34. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy:radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015; 16:e498-509; PMID:26433823; http://dx.doi.org/10.1016/S1470-2045(15)00007-8
35. La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors:New insights and current place in cancer therapy. Pharmacotherapy 2015; 35:963-76; PMID:26497482; http://dx.doi.org/10.1002/phar.1643
36. Deutsch E, Levy A, Chargari C. Radiation therapy and immunomodulation:Focus on experimental data. Cancer Radiotherapie 2015; 19:515-8.37; PMID:26293415; http://dx.doi.org/10.1016/j.canrad.2015.05.018
37. Botta C, Gulla A, Correale P, Tagliaferri P, Tassone P. Myeloid-derived suppressor cells in multiple myeloma:pre-clinical research and translational opportunities. Frontiers Oncol 2014; 4:348; PMID:25538892; http://dx.doi.org/10.3389/fonc.2014.00348
38. Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi MM, Gori Savellini G, Bestoso E, Apollinari S, Mannucci S, Marra M, et al. Cetuximab +/− chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer J Int Du Cancer 2012; 130:1577-89; PMID:21618510; http://dx.doi.org/10.1002/ijc.26181
39. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, Tassone P, et al. Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother 2012; 35:440-7; PMID:22576349; http://dx.doi.org/10.1097/CJI.0b013e31825943aa
40. Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 2008; 68:1319-29; PMID:18561247; http://dx.doi.org/10.1002/pros.20794
41. Leng C, Li Y, Qin J, Ma J, Liu X, Cui Y, Sun H, Wang Z, Hua X, Yu Y, et al. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. Oncology Reports 2016; 35:699-708; PMID:26718132; http://dx.doi.org/10.3892/or.2015.4435
42. Yu Z, Tan Z, Lee BK, Tang J, Wu X, Cheung KW, Lo NT, Man K, Liu L, Chen Z, et al. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells. Oncotarget 2015; 6:32426-38; PMID:26431275; http://dx.doi.org/10.18632/oncotarget.5856
43. Yuksel OH, Urkmez A, Akan S, Yldirim C, Verit A. Predictive value of the Platelet-To-Lymphocyte ratio in diagnosis of prostate cancer. Asian Pacific J Cancer Prevention 2015; 16:6407-12; PMID:26434851; http://dx.doi.org/10.7314/APJCP.2015.16.15.6407
44. Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, Busund LT, Bremnes RM, Richardsen E. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate 2014; 74:1452-61; PMID:25111810; http://dx.doi.org/10.1002/pros.22862
45. Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Translational Med 2014; 12:30; PMID:24475900; http://dx.doi.org/10.1186/1479-5876-12-30
46. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99:23-33; PMID:10520991; http://dx.doi.org/10.1016/S0092-8674(00)80059-8
47. Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 2005; 42:799-809; PMID:15829268; http://dx.doi.org/10.1016/j.molimm.2004.06.040
48. Hopken UE, Winter S, Achtman AH, Kruger K, Lipp M. CCR7 regulates lymphocyte egress and recirculation through body cavities. J Leukocyte Biol 2010; 87:671-82; PMID:20028772; http://dx.doi.org/10.1189/jlb.0709505
49. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944-51; PMID:19858404; http://dx.doi.org/10.1200/JCO.2008.19.6147
50. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12; PMID:10537110; http://dx.doi.org/10.1038/44385
51. Schultze FC, Andag R, Alwahsh SM, Toncheva D, Maslyankov S, Yaramov N, von Ahsen N, Brandhorst G, Walson PD, Oellerich M, et al. FoxP3 demethylation is increased in human colorectal cancer and rat cholangiocarcinoma tissue. Clin Biochem 2014; 47:201-5; PMID:24291052; http://dx.doi.org/10.1016/j.clinbiochem.2013.11.013
52. Lopes LF, Guembarovski RL, Guembarovski AL, Kishima MO, Campos CZ, Oda JM, Ariza CB, de Oliveira KB, Borelli SD, Ehara Watanabe MA. FOXP3 transcription factor:a candidate marker for susceptibility and prognosis in triple negative breast cancer. Biomed Res Int 2014; 2014:341654; PMID:24877082; http://dx.doi.org/10.1155/2014/341654
53. Ladoire S, Mignot G, Dalban C, Chevriaux A, Arnould L, Rebe C, Apetoh L, Boidot R, Penault-Llorca F, Fumoleau P, et al. FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Annals Oncol 2012; 23:2552-61; PMID:22431701; http://dx.doi.org/10.1093/annonc/mds028
54. Polcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, Sauerwald A, Keyver-Paik MD, Kübler K, Büttner R, et al. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Cancer Immunol Immunother 2010; 59:909-19; PMID:20087581; http://dx.doi.org/10.1007/s00262-010-0817-1
55. Lu LF, Rudensky A. Molecular orchestration of differentiation and function of regulatory T cells. Genes Dev 2009; 23:1270-82; PMID:19487568; http://dx.doi.org/10.1101/gad.1791009
56. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64; PMID:7636184
57. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-87; PMID:18510923; http://dx.doi.org/10.1016/j.cell.2008.05.009
58. Radstake TR, van der Voort R, ten Brummelhuis M, de Waal Malefijt M, Looman M, Figdor CG, et al. Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors. Annals Rheumatic Dis 2005; 64:359-67; PMID:15331393; http://dx.doi.org/10.1136/ard.2003.017566
59. Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers:a systematic review and meta-analysis. Scientific Reports 2015; 5:15179; PMID:26462617; http://dx.doi.org/10.1038/srep15179
60. Slovin S., Biomarkers for immunotherapy in genitourinary malignancies. Urologic Oncol 2015; 34:205–13; PMID:25791754; http://dx.doi.org/10.1016/j.urolonc.2015.02.007
61. Massari F, Ciccarese C, Calio A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, et al. Magnitude of PD-1, PD-L1 and T Lymphocyte expression on tissue from Castration-Resistant prostate adenocarcinoma:An exploratory analysis. Targeted Oncol 2015; 11(3):345–51; PMID:26566945; http://dx.doi.org/10.1007/s11523-015-0396-3
62. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8:239-45; PMID:17304234; http://dx.doi.org/10.1038/ni1443
63. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Eng J Med 2015; 373:1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643
64. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Eng J Med 2015; 373:123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
65. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced Renal-Cell Carcinoma. N Eng J Med 2015; 373:1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665
66. Bracarda S, Altavilla A, Hamzaj A, Sisani M, Marrocolo F, Del Buono S, Danielli R. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. Semin Oncol 2015; 42:495-505; PMID:25965369; http://dx.doi.org/10.1053/j.seminoncol.2015.02.004